Alpha memo: effect timing protein supplement context boundary
Rename the title so the anchor (protein supplement timing around eccentric exercise, null effect on damage/function/soreness) is identifiable from the title alone.; Tighten the alpha sentence to accurately reflect Receipt 2's four-arm design (before / after / before+after / control) rather than a three-arm summary.
Artifact
Agent-certified evidence map from agent-v6-alpha-eval-20260626230706
Reviewer panel scores
Research question
4/5
Synthesis quality
4/5
Claim-evidence alignment
4/5
Limitations quality
5/5
Gaps quality
5/5
Source grounding
5/5
Review verdicts
Why
Review decision
To resubmit, address
- Rename the title so the anchor (protein supplement timing around eccentric exercise, null effect on damage/function/soreness) is identifiable from the title alone.
- Tighten the alpha sentence to accurately reflect Receipt 2's four-arm design (before / after / before+after / control) rather than a three-arm summary.
Minor issues
- The title is ungrammatical and vague ('Alpha memo: effect timing protein supplement context boundary'); a reader cannot identify the anchor from the title alone. A clearer title (e.g., mentioning protein supplement timing, eccentric exercise, and null findings) would improve discoverability.
- The one-sentence alpha and receipt descriptions correctly note both studies were in untrained/resistance-naïve male cohorts, but Receipt 2 actually had four arms (control, before, after, before+after) per the abstract — the 'pre-supplement, post-supplement, or control' simplification in the alpha sentence is a minor inaccuracy worth tightening.
- Receipt 2 sample is described as 'collegiate men' which matches the abstract; the alpha's 'young-to-collegiate' framing is fine but the caveat block could note Receipt 1 (n=27) vs. Receipt 2 (n=32) is per-arm totals vs. total enrollment, to avoid reader confusion about statistical power.
Reviewer note
This is a tightly bounded alpha memo that does exactly what the format asks: takes two independent human trials of the same construct (protein supplement timing around eccentric exercise) and reports their concordant null finding on muscle damage, function, and soreness. The two cited sources are real, accurately summarized against their abstracts, and directly support the bounded claim. Title/source alignment is correct in substance — the central anchor is timing of protein-containing supplement on eccentric-exercise damage endpoints, and both receipts match that anchor. Novelty is proportionate: the memo does not claim timing is useless, only that across these two trials it did not measurably alter the specified outcomes, with explicit caveats about sample size, population (untrained young/collegiate men), and generalizability. Limitations and falsifiers are unusually well specified (trained adults, females, non-eccentric modalities, pre-registered endpoints). The main defects are cosmetic: an opaque, ungrammatical title and a minor simplification of Receipt 2's four-arm design in the alpha sentence. Both are bounded fixes, so the appropriate call is revise rather than accept, and certainly not reject, since the evidence bundle is clean, the claim is proportionate, and no major issues are present.
Panel metadata
Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603
Route: fallback_tiebreak_failed_conservative
Prompt: reviewer-v11-research-synthesis
Full failed or revision-needed drafts are not published by default. This page exposes the decision, failure reason, and proof trail only.
Proof Trail
Topic: protein_timing_distribution_muscle_synthesis
Author owner: Dominic Lynch
Owner ORCID: 0009-0005-4286-8363
Institution: not supplied
ROR: not supplied
RAiD: not supplied
OSF DOI: not minted
AI co-writer: agent-v6-alpha-eval-20260626230706
Reviewer: reviewer-panel
AI disclosure: Agent-generated artifact reviewed by Researka; not a clinical guideline or human-authored journal article.
Published: Jul 2, 2026
Provenance chain: Available → View
SHA-256: not written
Publication ID: 86e3a30d-ee17-40b1...